In this study, we developed three models based on clinical and/or [68Ga]Ga-PSMA PET-based radiomics features to redefine the inclusion criteria for AS in patients with biopsy Gleason Grade Group 1–2 PCa, which may have important clinical value in maximally reducing overtreatment and avoiding inappropriate adverse pathology patients progressing. The gene discussed is FOLH1; the disease is posterior cortical atrophy.